The global RNAi technology market is predicted to develop due to rising rates of chronic diseases like cardiovascular disease, cancer, diabetes, TB, AIDS, and others. RNA-based medicines can treat uncommon and hereditary diseases and chronic diseases. Heart disease kills 17.9 million people annually, followed by cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million), according to the WHO.RNAi therapy approvals are projected to boost the worldwide RNAi technology market throughout the forecast period. RNA-based therapies can treat many ailments, thus market participants are developing new ones. Novartis got FDA approval for Leqvio, a small interfering RNA (SiRNA) treatment for low-density lipoprotein, in December 2021.
The global RNAi Technology Market was valued at US$ 1,783.5 Mn in 2021 and is forecast to reach a value of US$ 3,506.5 Mn by 2028 at a CAGR of 10.1% between 2022 and 2028.
Leading Companies in the Rnai Technology Industry:
1. Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc was founded in 2006 and its headquters in Lexington, Massachusetts, United States. The company operates in 170 countries. In 2021 Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform.
2. Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. Company founded in 2011, and it’s located Marlborough, Massachusetts, United States .The Company operates in 50 Countries. In 2023 clinical stage Biotechnology Company who proprietary INTASYL™ RNAi platform technology is designed to make immune cells
3 Arcturus Therapeutics,
Arcturus Therapeutics,.was launch in 2013 and it’s headquarter located in San Diego, California, United States .it operate over 60 country. In2023 San Diego RNAi specialist Arcturus Therapeutics pulled in $5 million this week to support its RNAi tech,.
